Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients.

@article{Uramoto1999FasEI,
  title={Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients.},
  author={Hidetaka Uramoto and Toshihiro Osaki and Msatoshi Inoue and Satoshi Taga and Mitsuhiro Takenoyama and Takeshi Hanagiri and Ichiro Yoshino and Ryoichi Nakanishi and Yuji Ichiyoshi and Kosei Yasumoto},
  journal={European journal of cancer},
  year={1999},
  volume={35 10},
  pages={1462-5}
}
The aim of this study was to examine Fas expression in non-small cell lung cancer (NSCLC) and examine its correlation with clinicopathological features and prognosis. Fas expression was determined by an immunohistochemical analysis using the labelled streptavidin-biotin method from 220 paraffin specimens of completely resected primary stage I-III NSCLC. 80 (36%) of 220 cases were positive for Fas immunostaining. These 80 cases included 44 adenocarcinomas (33%) and 30 squamous cell carcinomas… CONTINUE READING